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There is a compelling scarcity of
pharmaceutical agents for efficacious, safe,
and affordable treatment of neglected
infectious or tropical diseases such as
malaria, trypanosomiasis, leishmaniasis,
dengue, lymphatic filariasis, and soil-
transmitted helminths, despite their high
prevalence in the developing world. Tox-
icity of drugs, microbial resistance pat-
terns, and long courses of treatments are
among the current challenges in effective
management of neglected diseases.
Lack of commercial market is often
outlined as the main factor for the limited
number of drugs against neglected diseas-
es. In the past 10 years, the product
research and development (R&D) pipeline,
including vaccines, diagnostics, and drugs,
for neglected diseases has been supported
through product development partner-
ships (PDPs) and others [1–3]. While
R&D activities for vaccines and diagnos-
tics for neglected diseases are centered on
the identification and evaluation of bio-
markers, development of new drugs is
presently focused on small molecules with
little or no ongoing effort for biopharma-
ceuticals.
Small molecule drug discovery and
development is a lengthy, risky, and costly
process. However, it has been shown that
the cost of developing drugs for neglected
diseases through public–private partner-
ship (PPP) and network models may be
significantly less, due to sharing the
financial burden between various agencies,
including government, philanthropic, and
private agencies [3] and adopting rational
criteria for lead progression [4].
Discovering leads with the potential to
become therapeutics is a critical step in
drug development. This involves a strong
interplay between various disciplines and
expertise in (i) biology, such as target
identification and validation, assay devel-
opment, screening, bioinformatics, and
ADME/T (absorption, distribution, me-
tabolism, and excretion/toxicology); and
(ii) chemistry, including medicinal chemis-
try, compound libraries and knowledge
management. Compound collections or
libraries containing hundreds, thousands,
or hundreds of thousands of small mole-
culesornaturalsubstancesmaybescreened
against molecular targets or whole cells
with variable results. When active hits are
identified from successful screens, they
undergo extensive characterization and
prioritization to rationalize further invest-
ment in optimizing them through extensive
structure-activity relationship (SAR) analy-
ses. These activities encounter harsh attri-
tion along every step of the discovery value
chain, not just at the level of a specific hit or
lead, but also during the selection and
validation of a molecular target as well as
assay development. Because these lead
discovery activities are of high risk, they
tend not to receive much funding from the
normal scientific granting bodies, and so
there is less incentive for academia to work
in this area [5].
In the absence of a perceived commer-
cial market for drugs against neglected
diseases, it is critical to devise sustainable
approaches to stimulate and fund R&D
activities in this field. In spite of the
progress made by existing PDPs, there
remain major hurdles to the discovery of
new chemical entities (NCEs) against
neglected diseases. An innovation gap
has therefore been defined for a range of
these diseases [4]. While some PDPs (e.g.,
Medicines for Malaria Venture and Drugs
for Neglected Diseases Initiative) have
done an excellent job in collaborating
with industry and academic institutions to
screen compound libraries against some of
the disease pathogens in vitro, many have
focused to a large extent on the so-called
‘‘low-hanging fruit’’, i.e., reformulation or
new combination of existing drugs or those
developed for other indications (Table 1).
To ensure a continued flow of promising
candidates into late-stage development,
discovery efforts must be maintained in a
sustainable manner and with active par-
ticipation of disease-endemic countries
(DECs) [4–6].
Several pre-competitive approaches have
been suggested for overcoming these chal-
lenges, including a more coordinated col-
laboration mechanism involving multidisci-
plinary networks of investigators and
partnerships between industry and public
sector in both developed and developing
countries [4,5,7]; a more open and cooper-
ative model where information and knowl-
edge are freely shared to support innovation
[8,9]; and the establishment of regional
networks of R&D centers in developing
countries to tackle the problems [10–13].
These more collaborative and empowering
research environments would increase the
efficiency and lower the cost of developing
new, safe, and effective medicines, vaccines,
and diagnostics while building indigenous
innovation capacity in developing countries
[4,12–15]. It will also bring different stake-
holders together to contribute their expertise
and knowledge in a coordinated way [4,5,8].
For instance, industry can contribute its
expertise, compound libraries, infrastructure,
training, and monetary or other in-kind
support; academic institutions can contri-
bute basic research and understanding of
pathogens, genomics, and whole cell assays;
while governments and non-governmental
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as manpower and finance.
A recurring difficulty for all screens
against neglected diseases is the availability
of high-quality compound libraries and the
resources to support the prioritization and
analysis of any resultant hits [5].In Figure 1
we describe an innovative partnership that
supports drug discovery against neglected
diseases as well as training of African
scientists through collaboration between a
public institute (the National Center for
Drug Screening, Shanghai [NCDS]), an
international agency (the Special Pro-
gramme for Research and Training in
Tropical Diseases [WHO/TDR]), and a
multinational biopharmaceutical company
(Novo Nordisk [NN]).
This collaboration was launched in July
2009 following a contractual agreement of
the parties and the initiation of the first
high-throughput screening (HTS) cam-
paign (Figure 2). The partnership focuses
on hit-to-lead activities against a range of
neglected diseases, including schistosomi-
asis and tuberculosis. It should be men-
tioned that some companies have estab-
lished in-house research facilities to
develop new drugs against neglected
diseases. For example, Novartis has set
up an institute in Singapore focusing on
malaria, dengue, and tuberculosis, and
AstraZeneca in India is working on
tuberculosis. GSK in Spain is now oper-
ating as an open laboratory to support
drug discovery for neglected diseases.
While these are all excellent efforts, more
efforts and investments are needed to
support sustainable health innovation in
developing countries.
Some recent inter-governmental actions
have stressed the need to invest in building
sustainable capacity for health innovation
in the developing world. Of note is the
Global Strategy and Plan of Action
(GSPOA) on public health, innovation,
and intellectual property, which aims to
promote new thinking on innovation and
access to medicines for diseases that
disproportionately affect developing coun-
tries [10]. It also calls for stronger PPPs and
North–South and South–South collabora-
tions, as well as the establishment of region-
al and international networks in support
of product innovation in disease-endemic
regions. This initiative is best exemplified by
the formation of the African Network for
Drugs and Diagnostics Innovation (ANDI),
whichoperatesunderaregionalgovernance
and management. ANDIhopes to provide a
time-efficient, cost-effective, and inclusive
model to meetcritical healthcarechallenges
in the continent [11–13] (Table 2). It is
Table 1. Product development partnerships (PDPs) focusing on drugs.
1) Institute of One World Health (http://www.iowh.org/)
2) Medicines for Malaria Venture (http://www.mmv.org/)
3) Drugs for Neglected Diseases Initiative (http://www.dndi.org/)
4) Global Alliance for TB Drug development (http://tballiance.org/)
Description # Type of organization: not-for-profit
# Operating model: virtual R&D
# Approach: building partnership with pharmaceutical industry, biotechnology companies, and academic institutions; utilizing
portfolio management approach
# Funding: philanthropy, governments, etc.
# Location: mainly in developed countries
# Capacity building: limited
doi:10.1371/journal.pntd.0001221.t001
Figure 1. Examples of public–private partnerships in drug discovery against
neglected diseases. NCDS - The National Center for Drug Screening, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences. Contribution: provides
infrastructure and expertise to conduct high-throughput screening (HTS) and identification of
leads for pharmaceutical development, as well as training of fellows from developing countries.
NN - Novo Nordisk A/S. Contribution: supply of compound libraries, expertise with
pharmaceutical research, development, and commercialization activities. WHO - World Health
Organization Special Programme for Research and Training in Tropical Diseases
(WHO/TDR). Contribution: oversees the management and technical review of the collaboration,
supplies molecular targets through academic collaborators to support HTS, provides access to
screening, medicinal chemistry, and DMPK networks, and sponsors fellows from Africa to be
trained at NCDS as part of the collaboration.
doi:10.1371/journal.pntd.0001221.g001
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NCDS, NN, and WHO/TDR collabora-
tion could, for example, be further opti-
mized and developed through regional
innovation networks in developing regions
like ANDI or other partners.
A broader interest has been expressed by
several stakeholder groups in Asia and
some preliminary mapping of innovation
centers is under way in China, India, and
several Association of Southeast Asian
Nations (ASEAN) countries. The Chinese
NDI held its first meeting in October 2009
and is in communication with its neighbor-
ing counterparts with the goal of creating a
pan-Asia network. The collaborative proj-
ect, described in Table 2, as well as
enthusiasm shown by other institutions in
China, including the National Institute of
Parasitic Diseases of the Chinese Center for
Disease Control and Prevention and the
Second Military Medical University, have
made a significant contribution towards the
establishmentoftheChineseNDI(Table3).
Cooperation among African, Asian, and
South American scientists is a good way to
promote South–South collaboration and
technology transfer.
In conclusion, we have described a few
innovative public–private and North–
South partnerships for drug development
against neglected diseases. Such partner-
ships are highly relevant in supporting
capacity building and establishment of
R&D infrastructures in developing coun-
tries. The hope is that these and other
emerging South–South activities will be
scaled up and sustained to support the
discovery, development, and delivery of
new drugs, diagnostics, vaccines, and
medical devices for diseases that dispro-
portionately affect developing countries.
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Figure 2. NCDS scientists and African fellows are analyzing the results obtained from
a TDR commissioned HTS campaign against a molecular target in tuberculosis (July
2009).
doi:10.1371/journal.pntd.0001221.g002
Table 2. Brief description of the African Network for Drugs and Diagnostics Innovation (ANDI).
# The ANDI concept was launched in Abuja, Nigeria, in 2008 (http://www.andi-africa.org/)
# ANDI is now hosted by the United Nations Economic Commission for Africa (UNECA) following the Memorandum of Understanding between the World
Health Organization (WHO) and UNECA
# ANDI has established a ministerial-level Board. The first Board meeting was held in January 2011 in Addis Ababa, Ethiopia. The Minister of Science and
Technology of South Africa and Minister of Public Health and Sanitation of Kenya were elected as co-chairs of the ANDI Board
Vision Create a sustainable platform for R&D innovation in Africa to address Africa’s own health needs
Mission Promote and sustain African-led health product innovation that addresses African public health needs through the assembly
of research networks, and build capacity to support human and economic development
Progress to date and future
activities
# 3 successful stakeholders meetings - first at Abuja in October 2008 in collaboration with the Nigerian government,
second at Cape Town in October 2009 in collaboration with the South African government, and third at Nairobi in
October 2010 in collaboration with the Kenyan government that attracted over 500 people in attendance
# Development and endorsement of the strategic business plan for ANDI by stakeholders
# ANDI Scientific and Technical Advisory Committee established
# Review of the first Pan-African Centers of Excellence in health innovation completed
# Review of the 1st ANDI call for projects in progress
# Ongoing advocacy and resource mobilization
# Establishment of 5 regional hubs in the 5 regions of Africa
# Establishment and funding of ANDI portfolio of projects
doi:10.1371/journal.pntd.0001221.t002
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Table 3. Brief description of the Chinese Network for Drugs and Diagnostics Innovation.
# Founded in October 2009 with the support of WHO/TDR and China’s CDC and Ministry of Science and Technology (http://www.asiandi.org/china/index.asp)
# Participants include major universities, research institutes, hospitals, multinational pharmaceutical giants, and biotech companies
Mission # Establishing a network that shares scientific information and technical resources to leverage product R&D activities nationwide
# Developing workable mechanisms by which PPPs in neglected diseases can flourish in China
# Assisting in intellectual property rights protection and advancing legitimate interests of the network members
Activities # R&D landscape mapping with initial phase of gap analyses on neglected disease in China completed. A formal report is being
completed and will be publicly available in 2011.
Organized an international workshop on quality in clinical research (June 2010).
Networking with other regional networks, including representation of China in the third Stakeholders Meeting and High Level
Forum of ANDI (October 2010, Nairobi, Kenya).
# First and second annual meetings of the Chinese NDI held in October 2009 and January 2011, respectively.
doi:10.1371/journal.pntd.0001221.t003
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